Injectable Dutasteride

Medical Options for Pattern Hair Loss

Some patients with androgenetic alopecia may be suitable for prescription treatment designed to influence the hormonal processes involved in follicular miniaturisation.

These treatments are not appropriate for everybody and should only be considered following clinical assessment, medical-history review and an informed discussion of potential benefits and risks.

At YT Medical, prescription treatment is therefore approached through consultation rather than allowing patients to select a medicine directly from the website.

Understanding DHT and Pattern Hair Loss

Male pattern hair loss is influenced by genetic susceptibility and a hormone called dihydrotestosterone (DHT).

In susceptible follicles, DHT contributes to progressive miniaturisation. Hairs become finer and shorter until affected follicles may eventually stop producing visible hair.

Certain prescription medicines act by reducing the production of DHT and may therefore be considered within medical management of androgenetic alopecia.

Why Is a Consultation Required?

Prescription options require consideration of factors including:

• The diagnosis and pattern of hair loss
• Age and medical history
• Current medication
• Previous hair-loss treatment
• Potential contraindications
• Possible side effects
• Fertility or family-planning considerations
• Psychological and sexual-health history
• Alternative treatment options

A patient’s preferred medicine will not automatically be prescribed simply because it has been requested.

Dutasteride and Hair Loss

Dutasteride is a 5-alpha-reductase inhibitor that reduces DHT production.

The British Association of Dermatologists notes that dutasteride can reduce DHT more strongly than finasteride, but also states that additional benefits over finasteride have not been convincingly demonstrated and that side effects may be more frequent or longer lasting.

Importantly, the current UK-licensed indication for dutasteride is benign prostatic hyperplasia rather than hair loss.

Any use for hair loss therefore requires appropriate clinical consideration and informed consent.

Safety and Informed Decision-Making

5-alpha-reductase inhibitors can be associated with sexual and psychological side effects.

In May 2026, the MHRA strengthened safety information for finasteride and dutasteride, including precautionary information concerning mood changes and sexual dysfunction.

These risks need to form part of an appropriate prescriber-led discussion.

Part of a Wider Hair-Loss Strategy

Prescription treatment may sometimes be considered alongside other aspects of hair management, including monitoring, regenerative treatments, hair-retention therapy or future hair transplantation.

The aim is to develop an appropriate long-term plan rather than simply prescribing a medication in isolation.